Tacrolimus, one of the most widely prescribed immunosuppressants in organ transplantation, carries a long list of potential side effects that range from mild nuisances to serious organ damage. The drug works by suppressing T-cell activity to prevent graft rejection, but that powerful immune suppression comes at a cost to the kidneys, pancreas, nervous system, and other tissues. Understanding the full picture matters because many of these effects are dose-dependent and manageable when caught early, while others are subtler and build over years.
Kidney Damage
Nephrotoxicity is the side effect that transplant teams worry about most, and it has been recognized since tacrolimus first entered clinical use. The drug causes both acute functional changes in renal blood flow and, over time, chronic structural damage including scarring of small arteries, patchy fibrosis between the tubules, and tubular atrophy.1Nephrology Dialysis Transplantation. Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation Repeated episodes of reduced blood flow to the kidney likely drive this progression from reversible constriction to permanent tissue injury. The irony for kidney transplant recipients is hard to miss: the drug that keeps your new organ alive can also slowly damage it.
In pediatric liver transplant patients, nephrotoxicity showed a clear relationship with blood levels of tacrolimus. When trough concentrations were around 11.8 ng/mL, kidney problems appeared more often than when levels sat closer to 6 ng/mL.2PubMed. A pharmacodynamic investigation of tacrolimus in pediatric liver transplantation That dose-dependence is one reason transplant clinics check tacrolimus blood levels so frequently, especially in the first months after surgery. Keeping levels in a therapeutic window that prevents rejection without poisoning the kidneys is a constant balancing act.
Post-Transplant Diabetes
Tacrolimus is the immunosuppressant most strongly linked to new-onset diabetes after transplantation. Roughly 30% of kidney transplant recipients develop post-transplant diabetes, and tacrolimus carries the highest rate among the available drugs.3PubMed Central. Beta-Cell Dysfunction Induced by Tacrolimus: A Way to Explain Type 2 Diabetes? The problem is not just insulin resistance; tacrolimus actively damages the insulin-producing beta cells in the pancreas.
Several mechanisms converge to explain this. Tacrolimus activates a signaling pathway that reduces levels of a key transcription factor called MAFA, which beta cells need to stay mature and functional. Under even mild metabolic stress, the drug essentially pushes beta cells into a state where they can no longer secrete insulin properly.4Diabetes. Tacrolimus-Induced BMP/SMAD Signaling Associates With Metabolic Stress–Activated FOXO1 to Trigger β-Cell Failure Research also shows tacrolimus inhibits a growth-regulation pathway in beta cells, further reducing their ability to produce and release insulin.5PubMed. Inhibition of the mTOR pathway: A new mechanism of β cell toxicity induced by tacrolimus In animal studies using transplanted human islet cells, tacrolimus impaired insulin secretion both during fasting and after a glucose challenge, confirming that the drug directly harms human beta cells at standard clinical doses.6The Journal of Clinical Investigation. Tacrolimus- and sirolimus-induced human β cell dysfunction is reversible and preventable
There is encouraging news embedded in those animal studies: the beta-cell dysfunction appeared to be reversible when the drug was stopped. But for transplant patients who need lifelong immunosuppression, “stop the drug” is rarely a realistic option. Instead, monitoring blood sugar closely and treating diabetes early become the practical priorities.
Neurological Side Effects
Tremor is probably the single most common symptom patients notice. In one survey of lung transplant recipients, 70% reported tremor.7PubMed. Symptom experience after lung transplantation: impact on quality of life and adherence It tends to be a fine hand tremor that makes writing, eating, and holding a phone annoying but not dangerous. Many patients describe it as the first thing they noticed after starting the drug.
At the more severe end, tacrolimus can cause a range of neurological problems from headaches and confusion to posterior reversible encephalopathy syndrome (PRES), a condition involving swelling in the brain that causes seizures and vision changes. A literature review cataloging reported cases found the spectrum runs from mild symptoms manageable with simple treatment all the way to serious conditions requiring urgent intervention.8PubMed. Tacrolimus-Induced Neurotoxicity After Transplant: A Literature Review In pediatric liver transplant patients, neurotoxicity was associated with trough levels around 15 ng/mL, well above the typical target range, reinforcing that higher blood levels raise the risk substantially.9PubMed. A pharmacodynamic investigation of tacrolimus in pediatric liver transplantation
Blood Pressure and Cardiovascular Effects
High blood pressure is common among transplant patients on tacrolimus, though tacrolimus appears somewhat less likely to cause it than cyclosporine, the older drug in the same class. In a head-to-head trial of cardiac transplant recipients, about 48% of those on tacrolimus developed new-onset hypertension needing medication over the first year, compared with 71% on cyclosporine.10PubMed. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus That same trial found tacrolimus was substantially less harmful to cholesterol levels: patients on cyclosporine had higher LDL, HDL, triglycerides, and total cholesterol throughout the year.
The blood pressure elevation appears to stem from the drug tipping the balance of substances that control blood vessel tone. Tacrolimus promotes the production of endothelin, a potent vessel constrictor, while impairing the synthesis of nitric oxide, which normally relaxes vessels.11PubMed. Posttransplantation hypertension related to calcineurin inhibitors Animal studies confirmed that tacrolimus increases endothelin content in the aortic wall and alters the receptors that respond to it.12PubMed. Changes by tacrolimus of the rat aortic proteome: involvement of endothelin-1 Over years, uncontrolled hypertension adds to the cardiovascular burden that transplant recipients already carry.
Electrolyte Disruptions
Tacrolimus impairs the kidney’s ability to handle magnesium and calcium in the tubules, causing the body to waste these minerals in the urine. The result is low magnesium, a condition that can cause muscle cramps, fatigue, and irregular heart rhythms. In one study of stable kidney transplant recipients, tacrolimus was associated with a nearly sevenfold higher risk of low magnesium.13Swiss Medical Weekly. Electrolyte disorders in stable renal allograft recipients In pediatric liver transplant patients, low magnesium was the single most frequently recorded adverse event.14PubMed. A pharmacodynamic investigation of tacrolimus in pediatric liver transplantation
High potassium is the other electrolyte problem to watch. Between 5% and 40% of patients on calcineurin inhibitors develop elevated potassium levels, which at high enough concentrations can disrupt heart rhythm.15PubMed. Electrolytes disturbances after kidney transplantation Both low magnesium and high potassium tend to be worst in the early months after transplantation and can often be managed with supplements or dietary adjustments, but they require regular blood monitoring to catch.
Gastrointestinal Problems
Diarrhea, nausea, and abdominal discomfort are common complaints on tacrolimus, though they can be hard to separate from effects of the other drugs transplant patients take simultaneously. Diarrhea affects a meaningful fraction of recipients and creates a particularly tricky clinical problem: when the intestinal lining is inflamed, it can lose the transport proteins that normally pump tacrolimus back out of gut cells. This means a bout of diarrhea can paradoxically cause tacrolimus blood levels to spike, increasing the risk of toxicity from the drug itself.16PubMed. Increased tacrolimus trough levels in association with severe diarrhea, a case report
In more severe cases, tacrolimus can cause direct inflammation of the colon. A study examining biopsy samples from patients with elevated tacrolimus levels found that 75% had diarrhea and more than half had visible colitis on endoscopy. The biopsies showed characteristic changes including damaged crypt cells, inflammation, and tissue regeneration patterns.17The American Journal of Surgical Pathology. Histologic Features of Tacrolimus-induced Colonic Injury This is worth knowing because tacrolimus-induced colitis can mimic infection or rejection, and misdiagnosing it could lead to treatment that makes things worse rather than better.
Hair Loss
Tacrolimus can trigger a type of diffuse, non-scarring hair loss called telogen effluvium, where a large proportion of hair follicles prematurely shift into their resting phase and begin shedding. In one study of female kidney-pancreas transplant recipients, roughly 29% of those on tacrolimus experienced clinically significant hair loss, compared with none on cyclosporine.18PubMed. Tacrolimus-induced alopecia in female kidney-pancreas transplant recipients The hair loss typically begins anywhere from one to fourteen months after starting the drug and appears to be related to tacrolimus-induced constriction of small blood vessels supplying hair follicles.19American Journal of Transplantation. Minireview Cutaneous Toxicities From Transplantation-Related Medications The good news is that the thinning resolves once tacrolimus is discontinued, though again, stopping the drug is not always an option.
Infections and BK Virus
Because tacrolimus suppresses the immune system, infections are an expected trade-off. One particular concern is BK virus, a polyomavirus that lies dormant in the kidneys of most people and reactivates when the immune system is heavily suppressed. Higher tacrolimus trough levels were independently associated with greater risk of BK virus appearing in the urine.20Annals of Transplantation. Risk Factors for Polyomavirus, Cytomegalovirus, and Viruria Co-Infection for Follow-Up of Renal Transplant Patients In one study, about half of recipients whose average tacrolimus trough levels exceeded 10 ng/mL developed BK viruria within two months of transplantation.21Scientific Reports. The association between serum tacrolimus concentrations and BK viruria in kidney transplant recipients Left unchecked, BK virus can progress to BK nephropathy, which damages the transplanted kidney and can lead to graft loss. Routine urine screening for BK virus is now standard practice at most transplant centers, and reducing tacrolimus doses when the virus is detected is typically the first response.
Thrombotic Microangiopathy
A rarer but serious blood complication is thrombotic microangiopathy, or TMA, in which small blood vessels develop clots that damage red blood cells as they pass through. TMA carries a high mortality rate and can affect the kidneys, brain, heart, lungs, and gut.22PubMed Central. Tacrolimus-Induced Thrombotic Microangiopathy After Orthotopic Heart Transplant: A Case Report Its symptoms can mimic other post-transplant problems, including rejection and infection, making early recognition challenging. Lab findings that point to TMA include a drop in platelet count, fragmented red blood cells on a blood smear, and rising kidney-function markers.23PubMed Central. Beyond Immunosuppression: The Intricate Relationship Between Tacrolimus and Microangiopathy If caught early, switching to a different immunosuppressant often allows recovery, but delays in diagnosis can lead to irreversible organ damage.
Drug Interactions That Amplify Side Effects
Tacrolimus is processed in the body primarily by the liver enzyme CYP3A4, which also handles a huge number of other drugs. Anything that slows down CYP3A4 raises tacrolimus levels, potentially tipping a patient from the safe range into toxicity. Antifungal drugs in the azole family are among the most clinically important offenders. All of the common triazole antifungals used to treat invasive fungal infections inhibit CYP3A4 and can cause tacrolimus to accumulate to dangerous concentrations.24PubMed. Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4 When one of these antifungals is started in a transplant patient, the tacrolimus dose usually has to be cut significantly, sometimes by half or more, with frequent level checks until a new stable dose is found.
Even food matters. Grapefruit juice inhibits intestinal CYP3A4 and raised tacrolimus blood levels by about 28% for total exposure and 73% for peak concentration in a study of extended-release tacrolimus.25PubMed Central. Assessment of the Intestinal CYP3A Contribution to Drug Interactions with Extended-Release Tacrolimus (LCPT) Using Grapefruit Juice Extended-release formulations were less affected than immediate-release versions, but the interaction was still clinically meaningful. Transplant pharmacists routinely educate patients about timing doses consistently with regard to meals, avoiding grapefruit, and steering clear of herbal supplements that might affect this enzyme.26PubMed Central. Tacrolimus Therapeutic Drug Monitoring in Kidney Transplant Patients Before and After Pharmacist Post-transplant Consults
Topical Tacrolimus Is a Different Story
Tacrolimus ointment, used to treat eczema and other inflammatory skin conditions, has a fundamentally different side-effect profile from the oral or intravenous forms. Because very little drug enters the bloodstream through the skin, the systemic toxicities described above are largely irrelevant. In clinical trials of tacrolimus ointment for atopic dermatitis, the drug was undetectable in 80% of blood samples collected, and when it was measurable, the concentrations were brief and not linked to adverse events.27PubMed. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety
The side effects of the ointment are mostly local: a burning or stinging sensation when first applied, itching, redness, and occasionally flu-like symptoms or headache. The burning was more pronounced in patients with severe disease and typically faded within the first few days of use. A lingering concern has been a theoretical risk of lymphoma with long-term topical use. A large European cohort study found the rate of lymphoma in adults using tacrolimus ointment was modestly higher than in those using topical corticosteroids, but the difference did not reach statistical significance. In children, the point estimate was higher but based on very few cases, making the confidence interval extremely wide.28Dove Press. A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation – JOELLE study) Regulatory agencies have kept a boxed warning on the product out of caution, but the epidemiological evidence so far has not confirmed a clear causal link.
Tacrolimus in Pregnancy
Pregnant transplant recipients face an unavoidable dilemma: stopping immunosuppression risks rejection and graft loss, but continuing it raises questions about fetal safety. The available evidence on tacrolimus is relatively reassuring. A review of published data concluded that tacrolimus does not appear to increase the risk of major birth defects above the baseline rate in the general population.29PubMed Central. Safety of tacrolimus in pregnancy Premature birth and low birth weight are frequently reported, but these are common in transplant pregnancies regardless of which immunosuppressant is used and likely reflect the mother’s underlying health. Kidney function and electrolytes should be monitored in newborns who were exposed to tacrolimus in the womb, because some reports have noted temporary high potassium and kidney impairment in these infants.
A retrospective study from Japan in patients with lupus confirmed this general picture. Tacrolimus use during pregnancy did not significantly affect the mother’s blood pressure in the third trimester or blood sugar levels in the first trimester compared to pregnancies without tacrolimus, and rates of adverse pregnancy outcomes did not differ between the groups.30PubMed. Safety of tacrolimus use during pregnancy and related pregnancy outcomes in patients with systemic lupus erythematosus: A retrospective single-center analysis in Japan
Genetic Variation and Pediatric Considerations
Not everyone metabolizes tacrolimus at the same rate, and genetic differences in the CYP3A5 enzyme play a meaningful role. In a study of pediatric liver transplant recipients, children who expressed the CYP3A5 enzyme (because they carried an active gene variant) had roughly double the risk of adverse drug reactions compared to non-expressers.31Therapeutic Drug Monitoring. Survival Time to Biopsy-Proven Acute Rejection and Tacrolimus Adverse Drug Reactions in Pediatric Liver Transplantation CYP3A5 expressers metabolize tacrolimus faster, which means they need higher doses to maintain therapeutic levels, and those higher doses increase the exposure of tissues to the drug. Some transplant programs now use pharmacogenomic testing before or shortly after transplantation to guide initial dosing, though this is not yet universal.
Children also present dosing challenges because their metabolism changes rapidly as they grow, and adolescents are particularly prone to missing doses. That adherence issue connects directly to side effects: erratic dosing causes tacrolimus levels to bounce between too low (risking rejection) and too high (risking toxicity).
How Side Effects Affect Adherence
The cumulative burden of tacrolimus side effects takes a real toll on quality of life, and that toll feeds back into how consistently patients take the drug. In a study of lung transplant recipients, patients who reported experiencing adverse effects were significantly more likely to take unauthorized “drug holidays,” skipping doses to get a break from the symptoms.32PubMed. Symptom experience after lung transplantation: impact on quality of life and adherence Symptom experiences negatively affected quality of life across every dimension measured. Tremor, in particular, was reported by 70% of the cohort, making it one of the most visible daily reminders that you are on a powerful drug. For transplant teams, recognizing that side effects erode adherence is not just an academic observation. It means that aggressively managing side effects, whether through dose adjustment, magnesium supplementation, blood pressure medication, or switching formulations, is actually part of preventing rejection, not just keeping patients comfortable.